DNA Binding Mode of the Cis and Trans Geometries of New Antitumor Nonclassical Platinum Complexes Containing Piperidine, Piperazine, or 4-Picoline Ligand in Cell-Free Media. Relations to Their Activity in Cancer Cell Lines
- 30 April 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 42 (20) , 6321-6332
- https://doi.org/10.1021/bi0342315
Abstract
The global modification of mammalian and plasmid DNAs by novel platinum compounds, cis- or trans-[PtCl(2)(NH(3))(Am)], where Am = NH(3), nonplanar heterocycle piperidine, piperazine, or aromatic planar heterocycle 4-picoline, was investigated in cell-free media using various biochemical and biophysical methods. These modifications have been compared with the activity of these new compounds in several tumor cell lines including those resistant to antitumor cis-diamminedichloroplatinum(II) (cisplatin). The results show that the replacement of the NH(3) group in cisplatin by the heterocyclic ligands does not considerably affect the DNA binding mode of this drug. Cytotoxicity studies have revealed that the replacement lowers the activity of the platinum compound in both sensitive and resistant cell lines. It has been suggested that the reduced activity of these analogues of cisplatin is associated with some features of the damaged DNA and/or its cellular processing. Alternatively, the reduced activity of the analogues of cisplatin might also be due to the factors that do not operate directly at the level of the target DNA, such as intracellular platinum uptake. In contrast to the analogues of cisplatin, the replacement of one ammine group by the heterocyclic ligand in its clinically ineffective trans isomer (transplatin) results in a radical enhancement of its activity in tumor cell lines. Importantly, this replacement also markedly alters the DNA binding mode of transplatin. The results support the view that one strategy of how to activate the trans geometry in bifunctional platinum(II) compounds including circumvention of resistance to cisplatin may consist of a chemical modification of the ineffective transplatin that results in an increased stability of its intrastrand cross-links in double-helical DNA and/or in an increased efficiency to form interstrand cross-links.Keywords
This publication has 14 references indexed in Scilit:
- DNA Interactions of Novel Platinum Anticancer DrugsPublished by Wiley ,2002
- Novel Apoptosis-Inducing trans-Platinum Piperidine Derivatives: Synthesis and Biological CharacterizationJournal of Medicinal Chemistry, 2002
- Novel Soluble Cationic trans-Diaminedichloroplatinum(II) Complexes that Are Active against Cisplatin Resistant Ovarian Cancer Cell LinesJournal of Medicinal Chemistry, 2002
- Current Status of Platinum-Based Antitumor DrugsChemical Reviews, 1999
- Structure, Recognition, and Processing of Cisplatin−DNA AdductsChemical Reviews, 1999
- trans-Platinum Compounds in Cancer Therapy: A Largely Unexplored Strategy for Identifying Novel Antitumor Platinum DrugsPublished by Springer Nature ,1999
- Anticancer Activity of Cisplatin and Related ComplexesPublished by Springer Nature ,1999
- Platinum-195 NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNAJournal of the American Chemical Society, 1990
- Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II)Chemico-Biological Interactions, 1988
- Interaction of nucleic acids with electrically charged surfacesBiophysical Chemistry, 1976